secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001493152-24-018798
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma Q1 net loss $4.0M ($0.39/shr); cash $21.8M; pipeline milestones on track
--------------------------------------------------------------------------------

- Net loss improved to $4.0M ($0.39/shr) from $5.2M ($0.64/shr) in Q1 2023.
- R&D expenses fell to $3.0M from $3.9M, driven by clinical-stage transitions.
- Cash at March 31, 2024: $21.8M, down from $26.4M; working capital $22.1M.
- Topline SAD results for oral CDI-988 (pan-coronavirus/norovirus) expected Q2 2024.
- Phase 2a influenza A study of CC-42344 enrollment complete; topline due H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224018798/0001493152-24-018798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224018798/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer